Intermediate for Afatinib. Afatinib (trade name: Gilotrif) is an irreversible covalent inhibitor of the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and erbB-2 (HER2) for the treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC). Afatinib has been approved by the U.S Food and Drug Administration on July 12, 2013.
Product Name: (S)-Tetrahydrofuran-3-ol
CAS Number: 86087-23-2
Molecular Weight:  88.106
Molecular Formula:  C4H8O2
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.